<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Bowman | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/tuneweeder78/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/tuneweeder78/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Bowman.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">d0add4a97124081a33153ae6fc06a4cf</guid>
				<title>Bowman posted an update: Additive manufacturing technologies have enabled the [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/41673/</link>
				<pubDate>Sat, 08 Feb 2025 10:09:34 -0800</pubDate>

									<content:encoded><![CDATA[<p>Additive manufacturing technologies have enabled the development of customised implants for craniomaxillofacial applications using biomaterials such as polymethylmethacrylate (PMMA), porous high-density polyethylene (pHDPE), and titanium mesh. This study aims to report an Australian manufacturer&#8217;s experience in developing, designing and supplying&hellip;<span class="activity-read-more" id="activity-read-more-41673"><a href="http://www.nationalboardinstitute.com/activity/p/41673/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">c6d6c98196df675045efc9409e911bbd</guid>
				<title>Bowman posted an update: he CNH groups, treatment with lenvatinib and pembrolizumab [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/39923/</link>
				<pubDate>Thu, 06 Feb 2025 11:02:04 -0800</pubDate>

									<content:encoded><![CDATA[<p>he CNH groups, treatment with lenvatinib and pembrolizumab is an attractive contemporary option for recurrence management. Molecular classification is a useful adjunct to conventional risk stratification paradigms for both prognostic counseling and treatment selection. Clinical trials incorporating molecular signatures in assigning treatment&hellip;<span class="activity-read-more" id="activity-read-more-39923"><a href="http://www.nationalboardinstitute.com/activity/p/39923/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">010b32a6720021c17cf349bd2c017c10</guid>
				<title>Bowman became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/30709/</link>
				<pubDate>Tue, 28 Jan 2025 15:37:33 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>